Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients

Sponsor
Karen Wonders (Other)
Overall Status
Recruiting
CT.gov ID
NCT04106609
Collaborator
(none)
70
1
2
27.3
2.6

Study Details

Study Description

Brief Summary

To test the effect of an individualized exercise oncology program on healthcare utilization, 30-day hospital readmission, pain, and cancer treatment tolerance.

Condition or Disease Intervention/Treatment Phase
  • Other: Supervised, individualized exercise oncology program
  • Other: Current standard of care
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Randomized, Controlled Trial of an Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients
Actual Study Start Date :
Aug 23, 2019
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exercise Group

Patients will complete a 60-minute exercise session once per week for 12 weeks. The exercise sessions will be individualized to the patient's needs and fitness level by a trainer. A patient will work with the same trainer throughout the study, who will plan the patient's individualized exercise regimen, and who will provide one-on-one supervision for the duration of each 60-minute session. Each 60-minute session will include cardiovascular, strength, and flexibility training. The intensity level for the aerobic exercise ranges from 30-45% of the individual's predicted VO2max, controlled by heart monitors and lasting 30 min. Strength training will involve a full body workout, with emphasis on all major muscle groups and employing machines, free weights, and resistance tubing. Patients will complete 3 sets of 10 repetitions for each strength exercise. Flexibility training will involve static stretching of all major muscle groups for 15-20 seconds at the completion of each workout.

Other: Supervised, individualized exercise oncology program
The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.

Active Comparator: Control Group

The control group will receive the current standard of care, which includes a resource guide with various options available to the cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.

Other: Current standard of care
Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.

Outcome Measures

Primary Outcome Measures

  1. Missed Fractions [12 weeks]

    Total number of missed fractions, determined by electronic medical record

  2. Numbers of Breaks in Cancer Treatment [12 weeks]

    Defined as missing 3 or more fractions due to patient condition, determined by electronic medical record

  3. Emergency room visits [12 weeks]

    Number of emergency room visits, determined by electronic medical record

  4. Encounters [12 weeks]

    Number of inpatient and outpatient hospital encounters, determined by electronic medical record

  5. Hospital readmission [12 weeks]

    Number of hospital readmissions for the same presenting issue, determined by electronic medical record

  6. Hospital length of stay [12 weeks]

    Hospital length of stay, in days, if applicable. Determined by electronic medical record.

  7. Cancer treatment adherence [12 weeks]

    Percentage of patient adherence to their cancer treatment, determined by electronic medical record

  8. Cancer treatment symptom management medications [12 weeks]

    Number of the different types of medications taken by patients for symptom management during their cancer treatment. Determined by electronic medical record.

  9. Cancer treatment related side effects [12 weeks]

    Total number of cancer treatment related side effects

  10. Patient rated pain score [12 weeks]

    patient rated pain measured by visual analog scale, determined by electronic. medical record. Scale is measured 0 to 10, with 0 being no pain and 10 being worst pain.

  11. Cancer treatment tolerance: Eastern Cooperative Oncology Group (ECOG) performance status score [12 weeks]

    Measured by the Eastern Cooperative Oncology Group (ECOG) performance status score. Scale is from 0 to 5, with 0 being high functioning and no restriction and 5 being dead

  12. Quality of life measure: McGill Quality of Life survey [12 weeks]

    MQOL was designed to measure quality of life of people at all stages of a life-threatening illness, from diagnosis to cure or death. MQOL assesses general domains applicable to all patients, incorporates the existential domain, balances physical and non-physical aspects of quality of life, and includes both positive and negative influences on quality of life. MQOL is a patient-reported instrument that employs 16 items plus a single-item global scale, each with a 2-day time frame. Five domains (physical well-being, physical symptoms, psychological, existential, and support) were identified through principal component analysis, and each of the domains is scored as a separate sub-scale. An overall index score can be calculated from the means of the five sub-scales. The single-item global quality of life scale is included as a validity variable but also can be used in conjunction with the overall MQOL and sub-scale scores.Each question uses a 0-10 scale with anchors at each end.

Secondary Outcome Measures

  1. Adherence rate [12 weeks]

    Exercise session adherence rate among the Exercise Group, collected from the Maple Tree Cancer Alliance participant records.

  2. Attrition rate [12 weeks]

    Exercise program attrition rate among the Exercise Group, collected from the Maple Tree Cancer Alliance participant records

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 80 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female; determined from electronic medical record

  • Initial stage 0, 1 or 2 breast cancer diagnosis within the past 12 weeks determined from electronic medical record

  • Age 30-80; determined from electronic medical record

  • Physician clearance to participate in exercise

Exclusion Criteria:
  • Participation in supervised physical exercise within 6 months prior to study enrollment

  • Currently pregnant or planning to become pregnant

  • Non-English speaking

  • Unable to make own medical decisions and/or to follow verbal instructions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Maple Tree Cancer Alliance Dayton Ohio United States 45404

Sponsors and Collaborators

  • Karen Wonders

Investigators

  • Principal Investigator: Karen Wonders, PhD, FACSM, Maple Tree Cancer Alliance

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Karen Wonders, Executive Director, Maple Tree Cancer Alliance, Kettering Health Network
ClinicalTrials.gov Identifier:
NCT04106609
Other Study ID Numbers:
  • Maple Tree Exercise
First Posted:
Sep 27, 2019
Last Update Posted:
Dec 10, 2020
Last Verified:
Dec 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 10, 2020